October 2020 – Biopharmanalyses

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

by

Anne-Lise Berthier

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics, a german biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of…..

Positive CHMP opinion for gene therapy Libmeldy™ for the treatment of Early-Onset Metachromatic Leukodystrophy

by

Anne-Lise Berthier

Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending full, or standard, marketing authorization for Libmeldy® (cryopreserved autologous CD34+ cells encoding the arylsulfatase-A, or ARSA,…..

NIH begins large clinical trial to test immune modulators for treatment of COVID-19

by

Anne-Lise Berthier

NIH begins large clinical trial to test immune modulators for treatment of COVID-19 The National Institutes of Health (NIH) has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response…..

EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

Positive CHMP opinion for gene therapy Libmeldy™ for the treatment of Early-Onset Metachromatic Leukodystrophy

NIH begins large clinical trial to test immune modulators for treatment of COVID-19

Pages

Archives

BIOPHARMANALYSES

Partenaires